Background: Breast cancer demands safe adjuvant to overcome the side effects of standard drug tamoxifen. Diet derived bioactive compounds are reported to exhibit modulation of cancer growth leading to cell death. Chickpea is a protein rich edible legume with several bioactive compounds that includes lectin as well. Characterization of chickpea lectin for its effect against cancer cells has been investigated in this study.
Method: Cicer arietinum L. lectin (CAL) agglutinating trypsin-treated rabbit blood cells was purified employing DEAE-cellulose and SP-sephadex ion exchange chromatography. The lectin was characterized for its biological activity vis-à-vis antiproliferative and apoptotic effects through cell cycle arrest in MCF-7 human breast cancer cells.
Result: There is a significant inhibition of the survival of breast cancer cells due to chickpea lectin in a dose dependent manner for 24 hr. Lectin treated cells revealed distinct features of apoptosis. Flow cytometric analysis at 80 µg/ml of lectin induced S and G2 phase cell cycle arrest. CAL induced apoptosis in MCF-7 cells associated with lactate dehydrogenase leakage, cell cycle arrest and reactive oxygen species generation.
Conclusion: Our studies show that chickpea lectin exerted anticancer activity and could be exploited as an essential source for medicine leading to the treatment of breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0929866525666180406142900 | DOI Listing |
J Transl Med
January 2025
Department of Stem Cell and Regenerative Medicine, Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Background: It is worthwhile to establish a prognostic prediction model based on microenvironment cells (MCs) infiltration and explore new treatment strategies for triple-negative breast cancer (TNBC).
Methods: The xCell algorithm was used to quantify the cellular components of the TNBC microenvironment based on bulk RNA sequencing (bulk RNA-seq) data. The MCs index (MCI) was constructed using the least absolute shrinkage and selection operator Cox (LASSO-Cox) regression analysis.
Chin Med
January 2025
Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is prevalent among patients receiving paclitaxel chemotherapy, which results in sensory abnormality as well as neuropathic pain. Conventional medications lack effectiveness on PIPN. Clinical trials identified beneficial effects of acupuncture on PIPN among patients receiving chemotherapy.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Te Aka Whai Ora (Māori Health Authority), Auckland, New Zealand.
Background: Breast cancer screening in Aotearoa New Zealand (NZ) still has persistent inequitable coverage by ethnicity, especially for Indigenous Māori women. This project aimed to undertake systematic data linkage to identify and invite eligible Māori women to participate in breast screening.
Methods: This is a cross-sectional observational study conducted in Northern New Zealand between 1/01/2020 and 30/06/2021.
Cancer Cell Int
January 2025
Department of Neurosurgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.
The tertiary lymphoid structure (TLS) is recognized as a potential prognosis factor for breast cancer and is strongly associated with response to immunotherapy. Inducing TLS neogenesis can enhance the immunogenicity of tumors and improve the efficacy of immunotherapy. However, our understanding of TLS associated region at the single-cell level remains limited.
View Article and Find Full Text PDFJ Transl Med
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, No.651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Background: HER2-targeted antibody-drug conjugates (ADCs) have revolutionized the treatment landscape of metastatic breast cancer. However, the efficacy of these therapies may be compromised by genomic alterations. Hence, this study aims to identify factors predicting sensitivity to HER2 ADC in metastatic breast cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!